QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

NGNE

QT80Neurogene Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
31.53
+0.74+2.40%
OverviewShort InterestFilings
NGNEQT80Neurogene Inc.·NASDAQ
OverviewShort InterestFilings
31.53+2.40%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-
Insider Own38.87%
Shs Outstand15.80M
Perf Week8.72%
Market Cap486.54MForward P/E-EPS next Y-5.59Insider Trans-0.20%Shs Float-Perf Month17.30%
Enterprise Value371.51MPEG0.86EPS next Q-1.43Inst Own-Short Float-Perf Quarter64.30%
Income-69867216.00P/S0.00EPS this Y-Inst Trans-Short Ratio-Perf Half Y61.44%
Sales-P/B2.89EPS next Y-0.28%ROA-37.48%Short Interest-Perf YTD53.06%
Book/sh15.06P/C-EPS next 5Y-ROE-37.88%52W High37.27 -15.40%Perf Year71.17%
Cash/sh15.38P/FCF-EPS past 3/5Y-ROIC-44.78%52W Low14.65 115.22%Perf 3Y-
Dividend Est.-EV/EBITDA-3.89Sales past 3/5Y-Gross Margin0.00%Volatility4.58% 5.03%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-6.31%Oper. Margin0.00%ATR (14)2.04Perf 10Y-
Dividend Ex-Date-Quick Ratio13.08Sales Y/Y TTM-Profit Margin0.00%RSI (14)64.02Recom2.17
Dividend Gr. 3/5Y-Current Ratio13.08EPS Q/Q-28.70%SMA2011.80%Beta1.65Target Price69.67
Payout0.00%Debt/Eq0.04Sales Q/Q-SMA5014.06%Rel Volume1.87Prev Close30.79
Employees107LT Debt/Eq0.03EarningsAug 10SMA20036.26%Avg Volume164.97KPrice31.53
IPO DateMar 07, 2014Option/ShortYes / YesEPS/Sales Surpr.-7.23% -Net Debt/EBITDA1.21Volume308,929Change2.40%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-09-26ReiteratedH.C. Wainwright$45 → $70
Jun-03-26InitiatedRodman & RenshawBuy$70
Apr-28-26InitiatedGuggenheimBuy$69
Oct-02-25ReiteratedH.C. Wainwright$50 → $45
May-16-25DowngradeBairdOutperform → Neutral
Apr-14-25ReiteratedBMO CapitalOutperform$45 → $16
Mar-25-25ReiteratedRobert W. Baird$46 → $38
Mar-25-25ReiteratedH.C. Wainwright$55 → $50
Nov-20-24ReiteratedStifel Nicolaus$60 → $46
Nov-12-24ReiteratedStifel Nicolaus$60
Latest News
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
FY 2017
12/31/2017
Total Revenue010
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A333
Gross Profit-3-2-3
Selling, General and Administrative Excl. Other252311
Research and Development756144
Other Operating Expense0-4-3
Operating Income-103-83-56
Interest Expense
000
Unusual Expense
———
Non-Operating Income (Expense)-13-7-19
Net Income Before Taxes-90-75-36
Income Taxes
000
Consolidated Net Income-90-75-36
Net Income From Continuing Operations-90-75-36
Net Income-90-75-36
EPS (Recurring)-4.24-4.28-2.83
EPS (Basic, Before Extraordinaries)-4.24-4.28-2.83
EPS (Diluted)-4.24-4.28-2.83
EBITDA-87-72-33
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio
———
Gross Margin—-200.00—
Operating Margin—-8,300.00—
Net Margin—-7,500.00—
Shares Outstanding211813
Market Capitalization433——
Operating Lease Expense
———
Insider Trading Volume
$38.75$36.18$33.61$31.03$28.46● Close Price0.00K93.27K186.53K279.80K373.06KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Cvijic Christine MikailPresident and CFOMay 06 '26Sale31.259,600300,04393,640May 08 12:00 AM
Jordan JulieChief Medical OfficerMar 26 '26Sale21.8982818,12812,472Mar 30 12:00 AM
Cvijic Christine MikailPresident and CFOMar 26 '26Sale21.622,55855,316103,240Mar 30 12:00 AM
McMinn RachelChief Executive OfficerMar 26 '26Sale22.073,35273,9951,344,307Mar 30 12:00 AM
Cobb StuartChief Scientific OfficerMar 13 '26Sale20.816,797141,44630,497Mar 17 12:00 AM
Cvijic Christine MikailPresident and CFOMar 13 '26Sale20.814,04584,176105,798Mar 17 12:00 AM
Cvijic Christine MikailPresident and CFOFeb 27 '26Sale25.114,800120,526109,843Mar 03 12:00 AM
Cobb StuartChief Scientific OfficerMay 14 '25Sale15.156,797103,00320,794May 15 12:00 AM
Cvijic Christine MikailPresident and CFOMar 13 '25Sale16.944,50176,24772,343Mar 17 12:00 AM
Samsara BioCapital GP, LLC10% OwnerNov 26 '24Buy25.8348,7701,259,6231,717,127Nov 27 12:00 AM
Cvijic Christine MikailPresident and CFONov 22 '24Buy20.4824,000491,40076,844Nov 25 12:00 AM
McMinn RachelChief Executive OfficerNov 22 '24Buy20.4047,500969,0001,297,859Nov 25 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR